Molecular & Cell Biophysics Lab, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Chromosoma. 2024 Jan;133(1):77-92. doi: 10.1007/s00412-023-00800-y. Epub 2023 May 31.
Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation. Single-cell DNAseq indeed reveals at least 8 distinct THP-1 aneuploid clones with further intra-clonal variation, suggesting ongoing genetic evolution. Importantly, acute inhibition of the mitotic spindle assembly checkpoint (SAC) produces CNV levels that are typical of high-CNV solid tumors, with subsequent cell death and down-selection to novel CNV. Pan-cancer analyses show p53 inactivation associates with aneuploidy, but leukemias exhibit a weaker trend even though p53 inactivation correlates with poor survival. Overexpression of p53 in THP-1 does not rescue established aneuploidy or LOH but slightly increases cell death under oxidative or confinement stress, and triggers p21, a key p53 target, but without affecting net growth. Our results suggest that factors other than p53 exert stronger pressures against aneuploidy in liquid cancers, and identifying such CNV suppressors could be useful across liquid and solid tumor types.
染色体的获得或丢失通常会导致拷贝数变异 (CNV) 和杂合性丢失 (LOH)。在癌症基因组图谱 (TCGA) 的数据中,与实体瘤相比,血液“液体”癌症中的这两种数量都较低,并且 LOH 影响基因组的比例约为 CNV 的一半。尽管这里有新的遗传异质性和扰动后 CNV 短暂升高的证据,但 p53 缺失的 THP-1 白血病衍生细胞的悬浮培养符合这些趋势。单细胞 DNAseq 确实揭示了至少 8 个不同的 THP-1 非整倍体克隆,进一步显示出克隆内变异,表明正在进行遗传进化。重要的是,有丝分裂纺锤体组装检查点 (SAC) 的急性抑制会产生与高 CNV 实体瘤相似的 CNV 水平,随后会发生细胞死亡和向新的 CNV 进行向下选择。泛癌症分析表明,p53 失活与非整倍体相关,但白血病的趋势较弱,尽管 p53 失活与较差的生存相关。THP-1 中 p53 的过表达不能挽救已建立的非整倍体或 LOH,但在氧化或限制应激下会轻微增加细胞死亡,并触发 p21,这是 p53 的关键靶标,但不会影响净生长。我们的结果表明,除了 p53 之外,其他因素在液体癌症中对非整倍体施加了更强的压力,并且鉴定出这种 CNV 抑制剂可能对液体和实体肿瘤类型都有用。